Compare Novartis AG (NVS) vs Onto Innovation (ONTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Onto Innovation — how do they compare? Novartis AG trades at $142.98 (market cap $268.57B), while Onto Innovation trades at $295 (market cap $14.36B). The key difference: Novartis AG is far larger — about 18.7× Onto Innovation's market cap, and Novartis AG pays a 3.31% dividend while Onto Innovation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Onto Innovation for 5 Days on average.
| NVS | ONTO | |
|---|---|---|
Market Cap | $268.57B | $14.36B |
Volume | 1,532,573 | 761,617 |
Sector | Health | Technology |
52-Week High | $168.62 | $378.45 |
52-Week Low | $121.80 | $121.34 |
Typical Hold Time | 82 Days | 5 Days |
Enterprise Value | $309.89B | $13.95B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Onto Innovation
Onto Innovation provides process control solutions for semiconductor manufacturing. Its inspection and metrology systems help chipmakers measure, analyze, and detect defects on wafers and advanced packages.
Read more on ONTO →
